Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohamad Tawila

Allergy & Immunology Royal Oak, MI Medical Doctor

NPI 1033134317 CMS profile 274078

3600 W 13 Mile Rd, Royal Oak, MI 48073

Open in the dashboard

General payments

$13,334

699 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohamad Tawila of Royal Oak, MI is reported in the CMS Open Payments database as having received $13,334 across 699 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,140 109
2024 General $2,273 109
2023 General $2,158 97
2022 General $2,183 114
2021 General $1,294 80
2020 General $1,180 75
2019 General $2,109 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohamad Tawila
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Mohamad Tawila were reported at $2,140. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Mohamad Tawila Allergy & Immunology median Middle half National median
2019 $2,109 $594 $163–$1,512 $163
2020 $1,180 $426 $106–$1,233 $114
2021 $1,294 $638 $157–$1,708 $132
2022 $2,183 $790 $205–$1,961 $149
2023 $2,158 $852 $220–$2,147 $160
2024 $2,273 $865 $203–$2,267 $164
2025 $2,140 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,698 120 payments
  2. GlaxoSmithKline, LLC. $2,284 156 payments
  3. CSL Behring $931 42 payments
  4. Regeneron Healthcare Solutions, Inc. $841 33 payments
  5. Amgen Inc. $838 51 payments
  6. OptiNose US, Inc. $785 35 payments
  7. Genzyme Corporation $741 38 payments
  8. Pfizer Inc. $482 30 payments
  9. Genentech USA, Inc. $472 20 payments
  10. Novartis Pharmaceuticals Corporation $392 20 payments
  11. Other $2,871 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,630 690 payments
  2. Education $257 4 payments
  3. Consulting Fee $223 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
  5. Honoraria $25 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA $1,501 59 payments
  2. DUPIXENT Immunology $1,170 56 payments
  3. NUCALA Immunology $943 55 payments
  4. Haegarda $795 36 payments
  5. Xhance $785 35 payments
  6. DUPIXENT Inflammation And Immunology $765 30 payments
  7. TEZSPIRE $757 48 payments
  8. TRELEGY ELLIPTA $666 57 payments
  9. AIRSUPRA $579 15 payments
  10. NUCALA Respiratory $563 34 payments
  11. Other $6,217 332 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

6,294

Median for Allergy/ Immunology: 449

Drug cost

$1,906,614

Median for Allergy/ Immunology: $169,700

Branded share of claims

37.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 130 $471,299
Xolair Omalizumab Brand 65 $221,231
Tezspire Tezepelumab-Ekko Brand 41 $162,614
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 212 $154,246
Dupixent Pen Dupilumab Brand 39 $145,617
Fasenra Pen Benralizumab Brand 18 $95,699
Fasenra Benralizumab Brand 16 $88,948
Breo Ellipta Fluticasone/Vilanterol Brand 150 $68,715
Spiriva Respimat Tiotropium Bromide Brand 95 $65,335
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 11 $61,903

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$1,193,074

Of which drugs: $868,362

Medicare patients

654

Average age 73

Services billed

59,216

442 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 51%
Diabetes 30%
Ischemic heart disease 28%
COPD 22%
Depression 21%
Osteoporosis 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 35 17,266 $511,725
Vaccine for influenza for injection into muscle 90662 Office 41 41 $3,355
Influenza vaccine, trivalent derived from cell cultures 90661 Office 32 32 $1,156

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $451
$451 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $336
  • GENZYME CORPORATION $85
$421 169 —
TEZSPIRE
  • Amgen Inc. $343
  • AstraZeneca Pharmaceuticals LP $76
$419 41 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $252
$252 34 —
Xhance
  • OptiNose US, Inc. $145
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

699 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record